ARQT Arcutis Biotherapeutics, Inc.
Healthcare$21.11+1.20%ClosedMarket Cap: $2.64B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
14.23
P/S
6.28
EV/EBITDA
202.59
DCF Value
$-164.74
FCF Yield
1.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
90.9%
Operating Margin
0.8%
Net Margin
-0.6%
ROE
-1.4%
ROA
-0.5%
ROIC
1.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $105.4M | 90.7% | $-9.1M | $-11.3M | $— | — |
| Q4 null | $129.5M | 91.0% | $18.4M | $17.4M | $— | — |
| FY null | $376.1M | 90.2% | $-12.2M | $-16.1M | $— | — |
| Q3 null | $99.2M | 91.2% | $8.5M | $7.4M | $— | — |
| Q2 null | $81.5M | 90.8% | $-14.6M | $-15.9M | $— | — |
| Q1 null | $65.8M | 86.6% | $-24.5M | $-25.1M | $— | — |
| Q4 null | $71.4M | 90.3% | $-7.6M | $-10.8M | $— | — |
| FY null | $196.5M | 90.3% | $-128.4M | $-140.0M | $— | — |
| Q3 null | $44.8M | 87.7% | $-39.1M | $-41.5M | $— | — |
| Q2 null | $30.9M | 88.8% | $-50.1M | $-52.3M | $— | — |
| Q1 null | $49.6M | 93.4% | $-31.6M | $-35.4M | $— | — |
| Q4 2023 | $13.5M | 83.4% | $-61.2M | $-66.3M | $-0.72 | — |